Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L. Scott, Mitchell E. Horwitz, Marcelo C. Pasquini et al.|Journal of Clinical Oncology|2017Cited by 664
Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J. Gibson, Benjamin L. Ebert, Alysia Bosworth et al.|Journal of Clinical Oncology|2017Cited by 468
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S. Hourigan, Mitchell E. Horwitz, Laura W. Dillon et al.|Journal of Clinical Oncology|2019Cited by 441
Emergence of a Clinical Daptomycin-Resistant <i>Staphylococcus aureus</i> Isolate during Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia and OsteomyelitisFrancisco M. Marty, Satish K. Pillai, Wendy W. Yeh et al.|Journal of Clinical Microbiology|2006Cited by 197